Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing
João Guilherme B De Marchi,1 Denise S Jornada,1 Fernanda K Silva,1 Ana L Freitas,2 Alexandre M Fuentefria,2 Adriana R Pohlmann,1,2 Silvia S Guterres1 1Pharmaceutical Sciences Graduate Program, 2Department of Organic Chemistry, Institute of Chemistry, Federal University of Rio Grande do S...
Guardado en:
| Autores principales: | , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Dove Medical Press
2017
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/9de5d5693af24818b101b45c396eb178 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:9de5d5693af24818b101b45c396eb178 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:9de5d5693af24818b101b45c396eb1782021-12-02T03:11:42ZTriclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing1178-2013https://doaj.org/article/9de5d5693af24818b101b45c396eb1782017-10-01T00:00:00Zhttps://www.dovepress.com/triclosan-resistance-reversion-by-encapsulation-in-chitosan-coated-nan-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013João Guilherme B De Marchi,1 Denise S Jornada,1 Fernanda K Silva,1 Ana L Freitas,2 Alexandre M Fuentefria,2 Adriana R Pohlmann,1,2 Silvia S Guterres1 1Pharmaceutical Sciences Graduate Program, 2Department of Organic Chemistry, Institute of Chemistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil Abstract: The use of nanoparticles may be particularly advantageous in treating bacterial infections due to their multiple simultaneous mechanisms of action. Nanoencapsulation is particularly useful for lipophilic drugs. In this scenario, triclosan is considered a good candidate due to its lipophilicity, broad-spectrum activity, and safety. In the present study, we have developed and characterized an antimicrobial suspension of triclosan and α-bisabolol against pathogenic strains that are resistant (Pseudomonas aeruginosa) and susceptible (Escherichia coli, Staphylococcus aureus, and Candida albicans) to triclosan. We also aimed to determine the minimum inhibitory concentration, using serial microdilution adapted from a CLSI methodology (Clinical and Laboratory Standards Institute). Challenge test was used to confirm the antimicrobial effectiveness of the nanocapsule formulation, as well as after its incorporation into a commercial wound dressing (Veloderm®). The zeta potential of P. aeruginosa before and after contact with cationic nanocapsules and the ratio between the number of nanocapsules per colony forming unit (CFU) were determined to evaluate a possible interaction between nanocapsules and bacteria. The results showed that nanoencapsulation has improved the antimicrobial activity when tested with two different methodologies. The number of nanocapsules per CFU was high even in great dilutions and the zeta potential was reverted after being in contact with the cationic nanocapsules. The nanocapsules were able to improve the activity of triclosan, even when tested within 28 days and when dried in the wound dressing. Keywords: antimicrobial effect, triclosan, α-bisabolol, chitosan, nanocapsulesDe Marchi JGJornada DSSilva FKFreitas ALFuentefria AMPohlmann ARGuterres SSDove Medical Pressarticleantimicrobial effecttriclosanα-bisabololchitosannanocapsulesMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol Volume 12, Pp 7855-7868 (2017) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
antimicrobial effect triclosan α-bisabolol chitosan nanocapsules Medicine (General) R5-920 |
| spellingShingle |
antimicrobial effect triclosan α-bisabolol chitosan nanocapsules Medicine (General) R5-920 De Marchi JG Jornada DS Silva FK Freitas AL Fuentefria AM Pohlmann AR Guterres SS Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| description |
João Guilherme B De Marchi,1 Denise S Jornada,1 Fernanda K Silva,1 Ana L Freitas,2 Alexandre M Fuentefria,2 Adriana R Pohlmann,1,2 Silvia S Guterres1 1Pharmaceutical Sciences Graduate Program, 2Department of Organic Chemistry, Institute of Chemistry, Federal University of Rio Grande do Sul, Porto Alegre, RS, Brazil Abstract: The use of nanoparticles may be particularly advantageous in treating bacterial infections due to their multiple simultaneous mechanisms of action. Nanoencapsulation is particularly useful for lipophilic drugs. In this scenario, triclosan is considered a good candidate due to its lipophilicity, broad-spectrum activity, and safety. In the present study, we have developed and characterized an antimicrobial suspension of triclosan and α-bisabolol against pathogenic strains that are resistant (Pseudomonas aeruginosa) and susceptible (Escherichia coli, Staphylococcus aureus, and Candida albicans) to triclosan. We also aimed to determine the minimum inhibitory concentration, using serial microdilution adapted from a CLSI methodology (Clinical and Laboratory Standards Institute). Challenge test was used to confirm the antimicrobial effectiveness of the nanocapsule formulation, as well as after its incorporation into a commercial wound dressing (Veloderm®). The zeta potential of P. aeruginosa before and after contact with cationic nanocapsules and the ratio between the number of nanocapsules per colony forming unit (CFU) were determined to evaluate a possible interaction between nanocapsules and bacteria. The results showed that nanoencapsulation has improved the antimicrobial activity when tested with two different methodologies. The number of nanocapsules per CFU was high even in great dilutions and the zeta potential was reverted after being in contact with the cationic nanocapsules. The nanocapsules were able to improve the activity of triclosan, even when tested within 28 days and when dried in the wound dressing. Keywords: antimicrobial effect, triclosan, α-bisabolol, chitosan, nanocapsules |
| format |
article |
| author |
De Marchi JG Jornada DS Silva FK Freitas AL Fuentefria AM Pohlmann AR Guterres SS |
| author_facet |
De Marchi JG Jornada DS Silva FK Freitas AL Fuentefria AM Pohlmann AR Guterres SS |
| author_sort |
De Marchi JG |
| title |
Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| title_short |
Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| title_full |
Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| title_fullStr |
Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| title_full_unstemmed |
Triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| title_sort |
triclosan resistance reversion by encapsulation in chitosan-coated-nanocapsule containing α-bisabolol as core: development of wound dressing |
| publisher |
Dove Medical Press |
| publishDate |
2017 |
| url |
https://doaj.org/article/9de5d5693af24818b101b45c396eb178 |
| work_keys_str_mv |
AT demarchijg triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT jornadads triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT silvafk triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT freitasal triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT fuentefriaam triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT pohlmannar triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing AT guterresss triclosanresistancereversionbyencapsulationinchitosancoatednanocapsulecontainingalphabisabololascoredevelopmentofwounddressing |
| _version_ |
1718401873754456064 |